RELAPSED/REFRACTORY AML
Clinical trials for RELAPSED/REFRACTORY AML explained in plain language.
Never miss a new study
Get alerted when new RELAPSED/REFRACTORY AML trials appear
Sign up with your email to follow new studies for RELAPSED/REFRACTORY AML, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for tough leukemia: drug targets resistant cancer cells
Disease control Not yet recruitingThis study tests a drug called olutasidenib in 25 adults with a specific genetic form of acute myeloid leukemia (IDH1 mutated) that has returned or not responded to treatment, especially after the drug venetoclax stopped working. Participants take olutasidenib pills twice daily f…
Matched conditions: RELAPSED/REFRACTORY AML
Phase: PHASE2 • Sponsor: Timothy Pardee • Aim: Disease control
Last updated May 26, 2026 09:54 UTC
-
New cell therapy takes on tough leukemia
Disease control Not yet recruitingThis study tests a new treatment for acute myeloid leukemia (AML) that has returned or not responded to standard therapy. It uses specially engineered immune cells from a healthy donor to target and kill cancer cells. The trial has two phases: first to find the safest dose, then …
Matched conditions: RELAPSED/REFRACTORY AML
Phase: PHASE1, PHASE2 • Sponsor: Nationwide Children's Hospital • Aim: Disease control
Last updated May 26, 2026 09:52 UTC